Summary
This article re-examines the issue of salivary therapeutic drug monitoring (STDM). The anatomy and physiology of saliva and the salivary glands, as well as the effects of disease and drugs on salivary secretion and composition, are discussed briefly. Drugs for which therapeutic drug monitoring (TDM) has been shown useful are individually considered to determine if salivary drug concentrations (Csal) are reflective of plasma free drug concentrations (Cup). That is, is the Csal/Cup ratio time- and concentration-independent, as supported by a review of literature data? The primary determinant which appears to govern the potential utility of STDM for many of the drugs is the pKa of the drug. Drugs which are not ionisable or are un-ionised within the salivary pH range (phenytoin, carbamazepine, theophylline) are candidates for STDM based on current literature data. Digoxin and cyclosporin are potential candidates for STDM; however, further studies are necessary to confirm these preliminary findings. On the basis of current literature data, STDM does not appear to be useful for other drugs therapeutically monitored in serum/plasma.
Similar content being viewed by others
References
Aitio M-L, Virtanen R, Lammintausta R. Disopyramide concentrations in saliva. International Journal of Clinical Pharmacology, Therapy and Toxicology 20: 68–72, 1982
Allen MA, Wrenn JM, Putney JW, Borzelleca JF. A study of the mechanism of transport of diphenylhydantoin in the rat submaxillary gland in vitro. Journal of Pharmacology and Experimental Therapeutics 197: 408–413, 1976
Allen UD, Guerriere M, Read SE, Detsky AS. Percutaneous injuries among health care workers. Archives of Internal Medicine 151: 2033–2040, 1991
Amberson WR, Hober R. The permeability of mammalian salivary glands for organic non-electrolytes. Journal of Cellular and Comparative Physiology 2: 201–221, 1932
Bachmann K, Forney Jr RB, Voeller K. Monitoring phenytoin in salivary and plasma ultrafiltrates of pediatric patients. Therapeutic Drug Monitoring 5: 325–329, 1983
Bailey M. Occupational HIV infection risk. Lancet 335: 1104–1105, 1990
Barchowsky A, Stargel WW, Shand DG, Routledge PA. Saliva concentrations of lidocaine and its metabolites in man. Therapeutic Drug Monitoring 4: 335–339, 1982
Bartels H, Gunther E, Wallis S. Flow-dependent salivary primidone levels in epileptic children. Epilepsia 20: 431–436, 1979
Baum BJ. Salivary gland fluid secretion during aging. Journal of the American Geriatric Society 37: 453–458, 1989
Baumann P, Tinguely D, Koeb L, Schopf J, Le PK. On the relationship between free plasma and saliva amitriptyline and nortriptyline. International Pharmacopsychiatry 17: 136–146, 1982
Blanchard J, Harvey S, Morgan WJ. Serum/saliva correlations for theophylline in asthmatics. Journal of Clinical Pharmacology 31: 565–570, 1991
Blitzer A. Inflammatory and obstructive disorders of salivary glands. Journal of Dental Research 66 (Special issue): 675–679, 1987
Bochner F, Hooper WD, Sutherland JM, Eadie MJ, Tyrer JH. Diphenylhydantoin concentrations in saliva. Archives of Neurology 31: 57–59, 1974
Boobis S, Trembath PW, Chambers RE, Edmunds AT, Carswell F. Salivary theophylline estimates: are they valid substitutes for plasma levels? Therapeutic Drug Monitoring 1: 485–493, 1979
Borzelleca JF, Cherrick HM. The excretion of drugs in saliva: antibiotics. Journal of Oral Therapeutics and Pharmacology 2: 180–187, 1965
Brugmann G, Kleinau E, Nolte R, Petruch F. Comparison of phenytoin determinations in plasma, plasma dialysate and saliva for control of antiepileptic therapy in children. Klinische Wochenschrift 57: 93–94, 1979
Burgen ASV. The secretion of non-electrolytes in the parotid saliva. Journal of Cellular Physiology 48: 113–138, 1956
Chang K, Chiou WL. Interactions between drug and saliva-stimulating parafilm and their implications in measurements of saliva drug levels. Research Communications in Chemical Pathology and Pharmacology 13: 357–360, 1976
Chiou WL, Chang K, Peng GW. Precaution in the monitoring of drug levels in saliva: abnormal salicylate levels after oral dosing. Journal of Clinical Pharmacology 16: 158–160, 1976
Coates JE, Lam SF, McGaw WT. Radioimmunoassay of salivary cyclosporin with use of 125I-labeled cyclosporin. Clinical Chemistry 34: 1545–1551, 1988
Cooper TB, Bark N, Simpson GM. Prediction of steady state plasma and saliva levels of desmethylimipramine using a single dose, single time point procedure. Psychopharmacology 74: 115–121, 1981
Cordonnier J, Van den Heede M, Heyndrickx A. Saliva concentrations of disopyramide cannot substitute the drug’s plasma concentrations. Journal of Analytical Toxicology 11: 179–181, 1987
Coudert JL, Lissac M, Parret J. A new appliance for the collection of human submandibular saliva. Archives of Oral Biology 31: 411–413, 1986
Coyle JD, Lima JJ. Procainamide. In Evans et al. (Eds) Applied pharmacokinetics: principles of therapeutic drug monitoring, 2nd ed., pp. 682–711, Applied Therapeutics Inc., Spokane, 1986
Danhof M, Breimer DD. Therapeutic drug monitoring in saliva. Clinical Pharmacokinetics 3: 39–57, 1978
Dawes C. Circadian rhythms in human salivary flow rate and composition. Journal of Physiology 220: 529–545, 1972
DeVane CL. Cyclic antidepressants. In Evans et al. (Eds) Applied pharmacokinetics: principles of therapeutic drug monitoring, 2nd ed., pp. 852–907, Applied Therapeutics Inc., Spokane, 1986
Dutta SK, Dukehart M, Narang A, Latham PS. Functional and structural changes in parotid glands of alcoholic cirrhotic patients. Gastroenterology 96: 510–518, 1989
Dvorchik BH, Vesell ES. Pharmacokinetic interpretation of data gathered during therapeutic drug monitoring. Clinical Chemistry 22: 868–878, 1976
Eadie MJ. Plasma level monitoring of anticonvulsants. Clinical Pharmacokinetics 1: 52–66, 1976
Ebden P, Leopold D, Buss D, Smith AP, Routledge PA. Relationship between saliva and free total plasma theophylline concentrations in patients with chronic airflow obstruction. Thorax 40: 526–529, 1985
Eeg-Olofsson O, Nilsson H, Tonnby B, Arvidsson J, Grahn P-A, et al. Diurnal variation of carbamazepine and carbamazepine-10,11-epoxide in plasma and saliva in children with epilepsy: a comparison between conventional and slow-release formulations. Journal of Child Neurology 5: 159–165, 1990
Frauendienst-Egger G, Bartels H, Pfuller H, Luther I, Beck I. Methotrexate concentrations in serum and saliva in children treated with high doses of methotrexate. Journal of Clinical Chemistry and Clinical Biochemistry 27: 228–229, 1989
Galeazzi RL, Benet LZ, Sheiner LB. Relationship between the pharmacokinetics and pharmacodynamics of procainamide. Clinical Pharmacology and Therapeutics 20: 278–289, 1976
Gelenberg AJ, Wojcik JD, Falk WE, Spring B, Brotman AW, et al. Clovoxamine in the treatment of depressed outpatients: a double-blind, parallel-group comparison against amitriptyline and placebo. Comprehensive Psychiatry 31: 307–314, 1990
Glass BJ. Drug-induced xerostomia as a cause of glossodynia. Ear, Nose and Throat Journal 68: 779–781, 1989
Goldsmith RF, Ouvrier RA. Salivary anticonvulsant levels in children: a comparison of methods. Therapeutic Drug Monitoring 3: 151–157, 1981
Groth U, Prellwitz, Jahnchen E. Estimation of pharmacokinetic parameters of lithium from saliva and urine. Clinical Pharmacology and Therapeutics 16: 490–498, 1974
Haeckel R. Interpretation of salivary drug concentrations. Journal of Clinical Chemistry and Clinical Biochemistry 27: 223–226, 1989a
Haeckel R. Procedures for saliva sampling. Journal of Clinical Chemistry and Clinical Biochemistry 27: 246–247, 1989b
Haeckel R, Bucklitsch I. The comparability of ethanol concentrations in peripheral blood and saliva: the phenomenon of variation in saliva to blood concentration ratio. Journal of Clinical Chemistry and Clinical Biochemistry 25: 199–204, 1987
Haeckel R, Muhlenfeld HM. Reasons for intraindividual inconsistency of the digoxin saliva to serum concentration ratio. Journal of Clinical Chemistry and Clinical Biochemistry 27: 653–658, 1989
Hoeprich PD, Warshauer DM. Entry of four tetracyclines in saliva and tears. Antimicrobial Agents and Chemotherapy 5: 330–336, 1974
Horning MG, Brown L, Mowlin J, Lertratanangkoon K, Kellaway P, et al. Use of saliva in therapeutic drug monitoring. Clinical Chemistry 23: 157–164, 1977
Hvidberg EF, Dam M. Clinical pharmacokinetics of anticonvulsants. Clinical Pharmacokinetics 1: 161–188, 1976
Inaba T, Kalow W. Salivary excretion of amobarbital in man. Clinical Pharmacology and Therapeutics 18: 558–562, 1975
Iisalo E. Clinical pharmacokinetics of digoxin. Clinical Pharmacokinetics 2: 1–16, 1977
Jacobson ED. Salivary secretion. In Johnson LR (Ed.) Gastrointestinal physiology, 2nd ed., pp. 46–54, CV Mosby, St Louis, 1981
Joubert PH, Aucamp BN, Muller FO. Digoxin concentrations in serum and saliva: relationship to ECG changes and dosage in healthy volunteers. British Journal of Clinical Pharmacology 3: 1053–1056, 1976
Jusko WJ, Gerbracht L, Golden LH, Koup JR. Digoxin concentrations in serum and saliva. Research Communications in Chemical Pathology and Pharmacology 10: 189–192, 1975
Kanto J, Sellman R, Laurikainen E. Saliva concentrations of lignocaine in healthy volunteers. British Journal of Clinical Pharmacology 13: 736–737, 1982
Kapil RP, Axelson JE, Mansfield IL, Edwards DJ, McErlane B, et al. Disopyramide pharmacokinetics and metabolism: effect of inducers. British Journal of Clinical Pharmacology 24: 781–791, 1987
Kelly HW, Hadley WM, Murphy SA, Skipper BG. Monitoring children on sustained release therapy by salivary theophylline levels. American Journal of Diseases of Children 135: 137–139, 1981
Kilpatrick CJ, Wanwimolruk S, Wing LMH. Plasma concentrations of unbound phenytoin in the management of epilepsy. British Journal of Clinical Pharmacology 17: 539–546, 1984
Koch-Weser J. Medical intelligence drug therapy disopyramide. New England Journal of Medicine 300: 957–962, 1979
Knoebel LK. Secretion and action of digestive juices, absorption. In Selkurt (Ed.) Physiology, pp. 571–602, Little Brown, Boston, 1966
Knott C, Bateman M, Reynolds F. Do saliva concentrations predict unbound theophylline concentrations? A problem re-examined. British Journal of Clinical Pharmacology 17: 9–14, 1984
Knott C, Hamshaw-Thomas A, Reynolds F. Phenytoin-valproate interaction: importance of saliva monitoring in epilepsy. British Medical Journal 284: 13–16, 1982
Knott C, Reynolds F. The place of saliva in antiepileptic drug monitoring. Therapeutic Drug Monitoring 6: 35–41, 1984
Knott C, Reynolds F. Citrate and salivary drug measurement. Lancet 1: 97, 1987
Knott C, Williams CP, Reynolds F. Phenytoin kinetics during pregnancy and the puerperium. British Journal of Obstetrics and Gynaecology 93: 1030–1037, 1986
Koup JR, Jusko WJ, Goldfarb AL. pH-Dependent secretion of procainamide into saliva. Journal of Pharmaceutical Sciences 64: 2008–2010, 1975
Koysooko R, Ellis EF, Levy G. Relationship between theophylline concentration in plasma or saliva in man. Clinical Pharmacology and Therapeutics 15: 454–460, 1974
Krivoy N, Rogin N, Greif Z, Ben-Aryeh N, Gutman D, et al. Relationship between digoxin concentration in serum and saliva in infants. Journal of Pediatrics 99: 810–811, 1981
Legg B, Rowland M. Cyclosporin: measurement of fraction unbound in plasma. Journal of Pharmacy and Pharmacology 39: 599–603, 1987
Levy RH, Wilensky AJ, Friel PN. Other antiepileptic drugs. In Evans et al. (Eds) Applied pharmacokinetics: principles of therapeutic drug monitoring, 2nd ed., pp. 540–569, Applied Therapeutics Inc., Spokane, 1986
Liftshitz M, Ben-Zvi, Z, Gorodischer R. Monitoring phenytoin therapy using citric acid-stimulated saliva. Therapeutic Drug Monitoring 12: 334–338, 1990
Lindahl G, Lonnquist B, Hedfors E. Lymphocytic infiltration and HLA-DR expression of salivary glands in bone marrow transplant recipients: a prospective study. Clinical and Experimental Immunology 72: 267–173, 1988
Mackichan JJ, Duffner PK, Cohen ME. Salivary concentrations and plasma protein binding of carbamazepine and carbamazepine 10,11-epoxide in epileptic patients. British Journal of Clinical Pharmacology 12: 31–37, 1981
Mandel ID. Relation of saliva and plaque to caries. Journal of Dental Research 53: 246–266, 1974
Matin SB, Wan SH, Karam JH. Pharmacokinetics of tolbutamide: prediction by concentration in saliva. Clinical Pharmacology and Therapeutics 16: 1052–1058, 1974
Matthews RW, Bhoola KD, Rasker JJ, Jayson MI. Salivary secretion and connective tissue disease in man. Annals of the Rheumatic Diseases 44: 20–26, 1985
McAuliffe JJ, Sherwin AL, Leppik IE, Fayle SA, Pippenger CE. Salivary levels of anticonvulsants: a practical approach to drug monitoring. Neurology 27: 409–413, 1977
McKeage MJ, Maling TJB. Saliva lithium: a poor predictor of plasma and erythrocyte levels. New Zealand Medical Journal 102: 559–560, 1989
Miles MV, Tennison MB, Greenwood RS, Benoit SE, Thorn MD, et al. Evaluation of the Ames Seralyzer for the determination of carbamazepine, phenobarbital, and phenytoin concentrations in saliva. Therapeutic Drug Monitoring 32: 501–510, 1990
Miles MV, Tennison, MB, Greenwood RS. Intraindividual variability of carbamazepine, phenobarbital, and phenytoin concentrations in saliva. Therapeutic Drug Monitoring 13: 166–171, 1991
Newton DW, Kluza RB. pKa values of medicinal compounds in pharmacy. Drug Intelligence and Clinical Pharmacy 12: 546–554, 1978
Nishihara K, Uchino K, Saitoh Y, Honda Y, Nakagawa F, et al. Estimation of plasma unbound phenobarbital concentration by using mixed saliva. Epilepsia 20: 37–45, 1979
Obach R, Borja J, Prunonosa J, Valles JM, Torrent J, et al. Lack of correlation between lithium pharmacokinetic parameters obtained from plasma and saliva. Therapeutic Drug Monitoring 10: 265–268, 1988
Paton RD, Logan RW. Salivary drug measurement: a cautionary tale. Lancet 2: 1340, 1986
Paxton JW, Donald RA. Concentrations and kinetics of carbamazepine in whole saliva, parotid saliva, serum ultrafiltrate, and serum. Clinical Pharmacology and Therapeutics 28: 695–702, 1980
Paxton JW, Whiting B, Stephen KW. Phenytoin concentrations in mixed, parotid, and submandibular saliva and serum measured by radioimmunoassay. British Journal of Clinical Pharmacology 4: 185–191, 1977
Perry R, Campbell M, Greda DM, Anderson L. Saliva lithium levels in children: their use in monitoring serum lithium levels and lithium side effects. Journal of Clinical Psychopharmacology 4: 199–202, 1984
Pieper JA, Rodman JH. Lidocaine. In Evans et al. (Eds) Applied pharmacokinetics: principles of therapeutic drug monitoring, 2nd ed., pp. 639–681, Applied Therapeutics Inc., Spokane, 1986
Piredda S, Monaco F. Ethosuximide in tears, saliva, and cerebrospinal fluid. Therapeutic Drug Monitoring 3: 321–323, 1981
Rashid MU, Bateman DN. Effect of intravenous atropine on gastric emptying, paracetamol absorption, salivary flow and heart rate in young and fit elderly volunteers. British Journal of Clinical Pharmacology 30: 25–34, 1990
Rasmussen F. Salivary excretion of sulphonamides and barbiturates by cows and goats. Acta Pharmacologica et Toxicologica 21: 11–19, 1964
Reynolds F, Ziroyanis PN, Jones NF, Smith SE. Salivary phenytoin concentrations in epilepsy and in chronic renal failure. Lancet 2: 384–386, 1976
Reuning RH, Geraets DR. Digoxin. In Evans et al. (Eds) Applied pharmacokinetics: principles of therapeutic drug monitoring, 2nd ed., pp. 570–623, Applied Therapeutics Inc., Spokane, 1986
Sankaranarayanan A, Goel A, Pant VLN. Variation in the relationship between serum and saliva lithium levels. International Journal of Clinical Pharmacology, Therapy and Toxicology 23: 365–366, 1985
Schmidt D, Kupferberg HJ. Diphenylhydantoin, phenobarbital, and primidone in saliva, plasma and cerebrospinal fluid. Epilepsia 16: 735–741, 1975
Schramm W, Annesley TM, Siegel GJ, Sackellares JC, Smith RH. Measurement of phenytoin and carbamazepine in an ultrafiltrate of saliva. Therapeutic Drug Monitoring 13: 152–160, 1991
Schroder H, Jensen KB, Brandsborg M. Lack of correlation between methotrexate concentrations in serum saliva and sweat after 24h methotrexate infusions. British Journal of Clinical Pharmacology 24: 537–541, 1987
Schubert MM, Izutsu KT. Iatrogenic causes of salivary gland dysfunction. Journal of Dental Research 66: 680–688, 1987
Schubert MM, Sullivan KM, Morton TH, Izutsu KT, Peterson DE, et al. Oral manifestations of chronic graft-v-host disease. Archives of Internal Medicine 144: 1591–1595, 1984
Siegel IA, Ben-Aryeh H, Gozal D, Colin AA, Szargel R, et al. Comparison of unbound and total serum theophylline concentrations with those of stimulated and unstimulated saliva in asthmatic children. Therapeutic Drug Monitoring 12: 360–364, 1990
Smith TW, Butler VP, Haber E. Determination of therapeutic and toxic serum digoxin concentrations by radioimmunoassay. New England Journal of Medicine 281: 1212–1216, 1969
Spector R, Park GD, Johnson GF, Vesell ES. Therapeutic drug monitoring. Clinical Pharmacology and Therapeutics 43: 345–353, 1988
Spencer EK, Campbell M, Adams P, Perry R, Choroco MC, et al. Saliva and serum lithium monitoring in hospitalized children. Psychopharmacology Bulletin 26: 239–243, 1990
Sreebny LM, Valdini A, Yu A. Xerostomia. Part II: relationship to nonoral symptoms, drugs, and diseases. Oral Surgery Oral Medicine Oral Pathology 68: 419–427, 1989
Steele WH, Stuart JFB, Whiting B, Lawrence JR, Calman KC, et al. Serum, tear and salivary concentrations of methotrexate in man. British Journal of Clinical Pharmacology 7: 207–211, 1979
Stephen KW, Speirs CF. Methods for collecting individual components of mixed saliva: the relevance to clinical pharmacology. British Journal of Clinical Pharmacology 3: 315–319, 1976
Stoehr GP, Venkataramanan R, Dauber JH. Comparison of methods for determining unbound theophylline concentrations. Therapeutic Drug Monitoring 8: 42–46, 1986
Svensson CK. Ethical considerations in the conduct of clinical pharmacokinetic studies. Clinical Pharmacokinetics 17: 217–222, 1989
Svensson CK, Woodruff MN, Baxter JG, Lalka D. Free drug concentration monitoring in clinical practice: rationale and current status. Clinical Pharmacokinetics 11: 450–469, 1986
Tokugawa K, Ueda K, Fujito H, Kurokawa T. Correlation between the saliva and free serum concentration of phenobarbital in epileptic children. European Journal of Pediatrics 145: 401–402, 1986
Tomlin PI, McKinlay I, Smith I. A study on carbamazepine levels, including estimation of 10,11-epoxy-carbamazepine and levels in free plasma and saliva. Developmental Medicine and Child Neurology 28: 713–718, 1986
Troupin AS, Friel P. Anticonvulsant levels in saliva, serum, and cerebrospinal fluid. Epilepsia 16: 223–227, 1975
Uden DL, Miller KW, Strand LM, Johnson PB, Zaske DE. Saliva-serum theophylline concentrations: substantial intrapatient and interpatient variation in predicting serum concentrations. Therapeutic Drug Monitoring 3: 143–150, 1981
Wagner SA, Slavik M. An individualized plastic intraoral device for the collection of human parotid saliva. International Journal of Clinical Pharmacology, Therapy and Toxicology 22: 236–239, 1984
Yosselson-Superstine S, Yanuka Y, Ishai S. Relationship between quinidine concentrations measured in saliva and erythrocytes, and in serum. International Journal of Clinical Pharmacology, Therapy and Toxicology 20: 181–186, 1982
Zaghloul I, Ptachcinski RI, Burckart GJ, Van Thiel D, Starzel TE, et al. Blood protein binding of cyclosporine in transplant patients. Journal of Clinical Pharmacology 27: 240–242, 1987
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Drobitch, R.K., Svensson, C.K. Therapeutic Drug Monitoring in Saliva. Clin. Pharmacokinet. 23, 365–379 (1992). https://doi.org/10.2165/00003088-199223050-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199223050-00003